Clinical trial
A Phase 2, Randomised, Multicentre Study to Assess the Dose Level of Multiple THR-149 Injections and to Evaluate the Efficacy and Safety of THR-149 Versus Aflibercept for the Treatment of Diabetic Macular Oedema (DME)
NCT04527107 is registered in ClinicalTrials.gov with Oxurion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomised, Multicentre Study to Assess the Dose Level of Multiple THR-149 Injections and to Evaluate the Efficacy and Safety of THR-149 Versus Aflibercept for the Treatment of Diabetic Macular Oedema (DME)
- Lead sponsor
- Oxurion
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2020
- Completion date
- November 22, 2023
- Enrollment
- 135 (actual)
- Sites
- 78
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes mellitus, diabetic macular edema, diabetic retinopathy